Sign in

    Richard Dorado • DDF

    Richard Dorado is a Vice President and Equity Research Analyst at DDF, specializing in the coverage of biotechnology and pharmaceutical companies with a deep focus on mid-cap and emerging growth firms such as Amgen, Gilead Sciences, and Vertex Pharmaceuticals. Renowned for his detailed clinical trial analysis and investment insights, Dorado has achieved a success rate exceeding 65% according to leading analyst ranking platforms, delivering double-digit average annualized returns for recommended equities. He began his career as an associate at Leerink Partners before joining DDF in 2018, steadily advancing through analyst ranks thanks to his strong industry expertise and quantitative prowess. Dorado holds FINRA Series 7, 63, and 86/87 registrations, establishing his professional credibility within the sector.

    Richard Dorado's questions to Milestone Scientific Inc (MLSS) leadership

    Richard Dorado's questions to Milestone Scientific Inc (MLSS) leadership • Q1 2024

    Question

    Dr. Richard Dorado questioned why influential anesthesiology associations and Key Opinion Leaders (KOLs) who have used the device are not more vocal in endorsing the technology to accelerate its adoption. He also asked for an update on the use of CompuFlo and claim submissions specifically within the labor and delivery market.

    Answer

    Executive Jan Haverhals acknowledged that gaining endorsements from large professional societies is a lengthy process, though discussions are ongoing. He explained the company is taking a different route by presenting abstracts at society meetings to share clinical results. He confirmed that existing KOLs are actively helping to open doors at other institutions, but internal hospital value assessment and financial committee approvals are still required. Haverhals noted the company's focus has been on the interventional pain market, which is larger than the labor and delivery segment, and that they are also engaging with neurosurgeons.

    Ask Fintool Equity Research AI